SCHEMBL4674121

SCHEMBL4674121

O=C(C=C(O)c1nn[nH]n1)c1cc(CCc2ccccc2)cn1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 1/20 0.39
CES1 P23141 1/20 0.38
NCEH1 Q6PIU2 1/20 0.38
GAA P10253 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
LMNA P02545 2/20 0.34
CXCR3 P49682 1/20 0.34
EPHX2 P34913 1/20 0.34
ALDH3A1 P30838 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673793 0.91 CES1 (0.38) CES1NCEH1GAAALDH1A1MEN1
SCHEMBL4676181 0.86 PSEN1 (0.36) GAAALDH1A1MEN1KMT2APSEN1
SCHEMBL4678102 0.85 CA2 (0.35) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL4675352 0.84 CMA1 (0.34) ALDH1A1LMNACXCR3CA2CA9
SCHEMBL4672992 0.81 CES1 (0.37) TBXA2RCES1NCEH1GAAALDH1A1
SCHEMBL4671561 0.81 CA2 (0.35) ALDH1A1PSEN1PSEN2APH1BNCSTN
SCHEMBL4672248 0.81 RAPGEF4 (0.39) TBXA2RALDH1A1MEN1KMT2APSEN1
SCHEMBL4673202 0.81 CA2 (0.34) TBXA2RALDH1A1LMNACXCR3CA2
SCHEMBL4674859 0.80 NOD2 (0.35) LMNA
SCHEMBL4671888 0.80 CES1 (0.44) CES1NCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 TBXA2R 2734/4885CES1 445/4885NCEH1 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.